Profusa, Inc. (NASDAQ:PFSA) Short Interest Update

Profusa, Inc. (NASDAQ:PFSA) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 665,135 shares, an increase of 1,666.7% from the April 15th total of 37,649 shares. Based on an average daily trading volume, of 2,488,159 shares, the days-to-cover ratio is currently 0.3 days. Currently, 17.0% of the shares of the stock are sold short.

Profusa Stock Down 7.0%

PFSA opened at $0.48 on Tuesday. The stock has a market cap of $2.11 million, a PE ratio of 0.00 and a beta of 0.47. The company has a 50-day simple moving average of $0.74. Profusa has a 12 month low of $0.41 and a 12 month high of $180.00.

Analyst Upgrades and Downgrades

PFSA has been the subject of a number of recent research reports. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.